postpartum depression - MGH Center for Women's Mental Health

Paroxetine and Cognitive-Behavioral Therapy (CBT) for the Treatment of Postpartum Depression (PPD)

Postpartum depression (PPD) is relatively common, occurring in about 10 to 15% of women after delivery. Non-pharmacologic interventions, including interpersonal psychotherapy, have been shown to be effective for the treatment of PPD. In addition, several reports have documented the efficacy of selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitor venlafaxine (Effexor). In a recent report, Misri and colleagues have evaluated whether the addition of Cognitive-Behavioral Therapy (CBT) to standard antidepressant treatment improves outcomes in women with postpartum depression and co-morbid anxiety.

By MGH Center for Women's Mental Health|2015-07-21T11:37:31-04:00September 20th, 2004|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Psychotherapy, Treatment|Comments Off

Prevention of Postpartum Depression

Postpartum depression (PPD) is a relatively common problem, affecting between 10% and 15% of women after delivery. Although it is difficult to reliably predict which women in the general population will experience postpartum mood disturbance, it is possible to identify certain subgroups of women who are more vulnerable to postpartum affective illness. Women who have had one episode of postpartum depression have about a 50% chance of experiencing another episode of PPD after a subsequent pregnancy. The extent to which a history of depression (prior to pregnancy) influences risk is less clear, but some studies indicate that between 30% and 50% will suffer from recurrent depression during the postpartum period. Several investigators have recently explored the potential efficacy of prophylactic interventions in these populations of women at risk.

By MGH Center for Women's Mental Health|2015-08-07T22:57:38-04:00July 20th, 2004|Postpartum Depression, Postpartum Psychiatric Disorders, Prevention|Comments Off

Is St. John’s Wort Safe in Breastfeeding Women?

Postpartum depression is a relatively common event, affecting 10 to 15% of women after the birth of a child. Many women, however, do not receive treatment, and one of the most common reasons for avoiding or deferring treatment is concern regarding the use of medications while breastfeeding. A preliminary study from Lee and colleagues at the Motherisk Program in Toronto, Canada has investigated the use of St. John’s wort in breastfeeding women.

By MGH Center for Women's Mental Health|2015-07-21T11:28:28-04:00January 18th, 2004|Antidepressants, Breastfeeding & Medications|Comments Off

Depression and Preterm Labor

Although most people tend to think of pregnancy as a time of emotional well-being, depression is relatively common, affecting about 1 in 10 women. While there are obvious concerns related to the use of antidepressants during pregnancy and the effects of these medications on the developing fetus, less attention has focused on the impact of depression itself on the pregnancy. A recent study suggests that women with depression may be at greater risk for preterm labor.

By MGH Center for Women's Mental Health|2015-07-20T10:48:28-04:00April 30th, 2002|Depressive Disorders, Outcomes, Pregnancy Outcomes, Psychiatric Disorders During Pregnancy|Comments Off

Venlafaxine for Postpartum Depression

Postpartum depression (PPD) is relatively common, occurring in about 10 to 15% of women after delivery. Several reports have documented the efficacy of selective serotonin reuptake inhibitors (SSRIs) sertraline, fluoxetine, and fluvoxamine for the treatment of this disorder. In a recent report, Cohen and colleagues have demonstrated the efficacy of venlafaxine for the treatment of PPD.

By MGH Center for Women's Mental Health|2016-03-28T13:24:00-04:00February 20th, 2002|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off